[DNA microarrays and prediction of clinical outcome in ovarian carcinoma patients].
Despite debulking surgery and taxane/platinum-based chemotherapy, ovarian cancer is the most lethal pelvic gynaecological cancer in western countries, with a 25% 5-years survival. Current histo-clinical prognostic factors are insufficient to capture the heterogeneous clinical outcome of patients. A better molecular characterization of the disease is crucial to refine the prognostic classifications and to identify new therapeutic targets. DNA microarrays, which allow the quantitative measurement of expression level of the whole genome simultaneously in a single tumor sample, have been recently used towards this objective with promising results. Here, we present and discuss the main published studies and the issues to address in the future to allow the expected transfer to clinical practice.
Sabatier
R
R
Centre de recherche en cancérologie de Marseille, Inserm U891, département d'oncologie moléculaire, Marseille, France. sabatierr@marseille.fnclcc.fr
Finetti
P
P
Cervera
N
N
Birnbaum
D
D
Bertucci
F
F
D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D006801:Humans; D020411:Oligonucleotide Array Sequence Analysis / Q000379:methods*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016896:Treatment Outcome
D000970:Antineoplastic Agents